8-KEarnings & ResultsRegulation FDExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Financial Results (Jul 27, 2023)

Filed July 27, 2023For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K on July 27, 2023, to report its second quarter 2023 financial results and related presentations. While the filing itself does not contain the detailed financial figures, it directs investors to an accompanying press release (Exhibit 99.1) and a presentation (Exhibit 99.2) for comprehensive information on the company's performance. These documents, available on the company's website, are crucial for understanding BMY's operational and financial standing for the period. Investors should note that the press release and presentation include non-GAAP financial measures, with reconciliations provided in the press release. The company has furnished these documents under Items 2.02 and 7.01, meaning they are not considered officially "filed" for purposes of Section 18 of the Exchange Act but are important for understanding the company's disclosed results and forward-looking initiatives.

Key Highlights

  • 1BMY released its second quarter 2023 financial results on July 27, 2023.
  • 2The 8-K filing includes an Earnings Press Release (Exhibit 99.1) with detailed financial results.
  • 3A Bristol Myers Presentation (Exhibit 99.2) covering financial and operating initiatives is also available.
  • 4Both furnished documents contain non-GAAP financial information, with reconciliations provided in the Earnings Press Release.
  • 5The information is furnished under Regulation FD and is not deemed "filed" for certain legal purposes.
  • 6Investors are directed to the company's website for the webcast and presentation details.

Frequently Asked Questions

The detailed financial results for the second quarter of 2023 are available in the Earnings Press Release (Exhibit 99.1) that was furnished with this 8-K filing. You can also find this information on the company's website or in the presentation materials (Exhibit 99.2).

When information is 'furnished' under Items 2.02 and 7.01 of an 8-K, it means the company is providing it to the public to comply with disclosure rules like Regulation FD. However, it is not considered officially 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, which could limit certain liabilities associated with those specific disclosures. This is a common practice for earnings releases.

While the 8-K filing itself does not contain detailed strategic updates, the accompanying Bristol Myers Presentation (Exhibit 99.2) is described as covering 'certain financial and operating initiatives.' Investors should review this presentation for potential insights into the company's forward-looking plans.

The Earnings Press Release and the Bristol Myers Presentation include references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures, along with explanations for their use, are available within the Earnings Press Release (Exhibit 99.1).